Drugs / HS-IT101
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05539768 | Oct 2022 → Dec 2023 overdue | neoplasm | The Affiliated Hospital of Qingdao University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05505812 | Oct 2022 → Dec 2023 overdue | breast cancer | The Affiliated Hospital of Qingdao University | Not yet recruiting | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07830342 | Sep 2026 → Oct 2028 expected | non-small cell lung carcinoma | Hangzhou Huasai Biomedicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07770802 | Aug 2026 → Aug 2028 expected | clear cell renal carcinoma | Hangzhou Huasai Biomedicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07105176 | Aug 2025 → Aug 2026 overdue | non-small cell lung carcinoma | Qingdao Sino-Cell Biomedicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06941818 | Jul 2025 → May 2026 overdue | melanoma | Qingdao Sino-Cell Biomedicine Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06342336 | Jan 2024 → Mar 2026 overdue | neoplasm | Qingdao Sino-Cell Biomedicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07406724 | Feb 2026 → Dec 2027 expected | melanoma | Qingdao Sino-Cell Biomedicine Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-IT101 | “A Single-Arm, Open-Label, Interventional Study to Evaluate the Efficacy of HS-IT101 Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy After Lymphodepleting...” NCT07830342 ↗ |
| Modality | Cell therapy | “adoptive cell therapy (ACT)” NCT05505812 ↗ |
| Route | Intravenous | “autologous TIL to patients i.v. in 30-60 minutes” NCT05505812 ↗ |